Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Total Non-Current Liabilities (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 5 years of Total Non-Current Liabilities data on record, last reported at $208.1 million in Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 36.52% year-over-year to $208.1 million; the TTM value through Dec 2025 reached $208.1 million, up 36.52%, while the annual FY2025 figure was $208.1 million, 36.52% up from the prior year.
  • Total Non-Current Liabilities reached $208.1 million in Q4 2025 per TARS's latest filing, up from $189.3 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $208.1 million in Q4 2025 and bottomed at -$202.8 million in Q3 2022.
  • Average Total Non-Current Liabilities over 4 years is $72.6 million, with a median of $66.8 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: rose 18.81% in 2023, then skyrocketed 212.78% in 2024.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $34.9 million in 2022, then soared by 91.48% to $66.8 million in 2023, then soared by 128.38% to $152.5 million in 2024, then soared by 36.52% to $208.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $208.1 million in Q4 2025, $189.3 million in Q3 2025, and $152.5 million in Q4 2024.